Skip to content
DataLookout
Menu

NCT07729462

A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine

StatusRecruiting
PhasePhase 3
SponsorPfizer
Primary completion (estimated)

At risk: Primary completion moved 39 days later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Oct 15, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 19 → 38 locations
  2. Minor Study sites: 19 to 21
  3. Minor Trial sites expanded: 4 → 19 locations
  4. Notable Recruitment opened Show 6 more changesShow less
    • Eligibility criteria expanded, about 22 words
    • Primary completion pushed from Sep 12, 2028 to Oct 21, 2028
    • Study completion pushed from Dec 11, 2028 to Jan 19, 2029
    • Start date changed from estimate of Jul 29, 2026 to Aug 26, 2026
    • Secondary endpoints: details revised at 6 of 7 entries
    • Site details revised at 4 of 4 sites
  5. Minor Study sites: 2 to 4v2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change From Observation Phase in Monthly Migraine Days (MMDs) Over the Entire Double-Blind Treatment Phase
Timeframe: 12 Weeks

Secondary (7)

Percentage of Participants Achieving a ≥50% Reduction From the Observation Phase in Monthly Migraine Days (MMDs) Over the Entire Double-Blind Treatment Phase
Change From Observation Phase in Moderate or Severe Monthly Headache Days Over the Entire Double-Blind Treatment Phase
Change From Observation Phase in Monthly Acute Migraine Medication Use Days Over the Entire Double-Blind Treatment Phase
Change From Baseline in Migraine-Specific Quality of Life Questionnaire (MSQ) Restrictive Role Function Domain Score
Change From Observation Phase in Monthly Migraine Days Over the Entire Double-Blind Treatment Phase in Participants With Historical Medication Overuse Headache and Medication Overuse
Show 2 moreShow less
Change From Baseline in MSQ Restrictive Role Function Domain Score in Participants With Historical Medication Overuse Headache and Medication Overuse
Percentage of Participants Achieving Medication Overuse Headache Remission

Arms and interventions

Rimegepant 75 mg orally disintegrating tablet (ODT) once dailyExperimental

Participants will receive rimegepant 75 mg orally disintegrating tablet (ODT) once daily during the 12-week double-blind treatment phase. Eligible participants may subsequently enter a 12-week open-label extension phase and receive open-label rimegepant 75 mg once daily. During the open-label extension phase, participants may also take an additional dose of rimegepant 75 mg for the acute treatment of breakthrough migraine attacks, up to 10 doses per month.

Matching placebo once daily for 12 weeks during the double-blind treatment phasePlacebo comparator

Participants will receive matching placebo once daily during the 12-week double-blind treatment phase. Eligible participants may subsequently enter a 12-week open-label extension phase and receive open-label rimegepant 75 mg once daily. During the open-label extension phase, participants may also take an additional dose of rimegepant 75 mg for the acute treatment of breakthrough migraine attacks, up to 10 doses per month.

Drugs: Rimegepant, Placebo

Sites

38 sites in 4 countries

United States 22, China 6, Israel 5, United Kingdom 5